Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | GPR34 | Q9UPC5 | 8/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | YAP1 | P46937 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619550 | 0.95 | MEN1 (0.58) | MEN1ALDH1A1LMNAKMT2AGPR34 | |
| SCHEMBL313024 | 0.91 | MEN1 (0.54) | MEN1ALDH1A1LMNAKMT2AGPR34 | |
| SCHEMBL313641 | 0.88 | ALDH1A1 (0.57) | MEN1ALDH1A1LMNAKMT2AGPR34 | |
| SCHEMBL2619549 | 0.86 | MDM4 (0.65) | MEN1ALDH1A1LMNAKMT2AMDM4 | |
| SCHEMBL313542 | 0.85 | MEN1 (0.49) | MEN1ALDH1A1LMNAKMT2AGPR34 | |
| SCHEMBL1862350 | 0.85 | MEN1 (0.61) | MEN1ALDH1A1LMNAKMT2AGPR34 | |
| SCHEMBL313074 | 0.84 | MDM4 (0.55) | MEN1ALDH1A1LMNAKMT2AGPR34 | |
| SCHEMBL313083 | 0.83 | ALDH1A1 (0.48) | MEN1ALDH1A1LMNAKMT2AGPR34 | |
| SCHEMBL313537 | 0.83 | MEN1 (0.58) | MEN1ALDH1A1LMNAKMT2APPARG | |
| SCHEMBL2619554 | 0.82 | GPR34 (0.70) | MEN1ALDH1A1LMNAKMT2AGPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664426-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664426-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664426-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130317118-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8519175-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519175-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519175-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130030061-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030061-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309754-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120094994-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094994-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094994-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-8093420-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093420-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093420-B2 | Functionalized amino acids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2007047244-A2 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098180-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BCAT2, BCAT1, SLC7A1 | MEN1 2243/4885ALDH1A1 1912/4885LMNA 3673/4885 |
| US-20120094994-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BCAT2, BCAT1, SLC7A1 | MEN1 2243/4885ALDH1A1 1912/4885LMNA 3673/4885 |
| US-20130030061-A1 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM | BCAT2, BCAT1, SLC7A1 | MEN1 2243/4885ALDH1A1 1912/4885LMNA 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.